Do analysts recommend ACTG or CNTN?

Acacia Research currently has a consensus target price of $6.00, indicating a potential upside of 29.87%. Given Acacia Research's stronger consensus rating and higher probable upside, analysts plainly believe Acacia Research is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acacia Research 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor ACTG or CNTN?

In the previous week, Acacia Research had 3 more articles in the media than Hillstream Biopharma. MarketBeat recorded 5 mentions for Acacia Research and 2 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 0.89 beat Acacia Research's score of 0.59 indicating that Hillstream Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acacia Research 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Hillstream Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate FWDI or CNTN?

Forward Industries presently has a consensus price target of $7.45, suggesting a potential upside of 74.07%. Given Forward Industries' stronger consensus rating and higher possible upside, equities analysts clearly believe Forward Industries is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Forward Industries 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor FWDI or CNTN?

In the previous week, Forward Industries had 3 more articles in the media than Hillstream Biopharma. MarketBeat recorded 5 mentions for Forward Industries and 2 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 0.89 beat Forward Industries' score of -0.21 indicating that Hillstream Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forward Industries 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Hillstream Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate MAAS or CNTN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maase 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, MAAS or CNTN?

Maase has higher revenue and earnings than Hillstream Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maase $784.35M 0.42 -$27.36M N/A N/A Hillstream Biopharma N/A N/A -$35.92M -$1.15 N/A

Is MAAS or CNTN more profitable?

Maase's return on equity of 0.00% beat Hillstream Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Maase N/A N/A N/A Hillstream Biopharma N/A -31.50% -24.72%

Does the media favor MAAS or CNTN?

In the previous week, Maase and Maase both had 2 articles in the media. Hillstream Biopharma's average media sentiment score of 0.89 beat Maase's score of 0.67 indicating that Hillstream Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maase 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hillstream Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CEPO or CNTN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cantor Equity Partners 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, CEPO or CNTN?

Cantor Equity Partners is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cantor Equity Partners N/A N/A -$6.66M -$0.47 N/A Hillstream Biopharma N/A N/A -$35.92M -$1.15 N/A

Is CEPO or CNTN more profitable?

Cantor Equity Partners' return on equity of 0.00% beat Hillstream Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Cantor Equity Partners N/A N/A -2.95% Hillstream Biopharma N/A -31.50% -24.72%

Does the media prefer CEPO or CNTN?

In the previous week, Cantor Equity Partners had 1 more articles in the media than Hillstream Biopharma. MarketBeat recorded 3 mentions for Cantor Equity Partners and 2 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 0.89 beat Cantor Equity Partners' score of 0.53 indicating that Hillstream Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cantor Equity Partners 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hillstream Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CNTN or TROO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TROOPS 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, CNTN or TROO?

TROOPS has higher revenue and earnings than Hillstream Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hillstream Biopharma N/A N/A -$35.92M -$1.15 N/A TROOPS $17.10M 14.00 -$27.91M N/A N/A

Is CNTN or TROO more profitable?

TROOPS's return on equity of 0.00% beat Hillstream Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Hillstream Biopharma N/A -31.50% -24.72% TROOPS N/A N/A N/A

Does the media refer more to CNTN or TROO?

In the previous week, TROOPS had 2 more articles in the media than Hillstream Biopharma. MarketBeat recorded 4 mentions for TROOPS and 2 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 0.89 beat TROOPS's score of -0.31 indicating that Hillstream Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hillstream Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TROOPS 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Hillstream Biopharma (CNTN) Competitors

$1.90 +0.03 (+1.60%)

Closing price 04:00 PM Eastern

Extended Trading

$1.88 -0.01 (-0.79%)

As of 07:45 PM Eastern

Compare

CNTN vs. ACTG, FWDI, MAAS, CEPO, and TROO

Should you buy Hillstream Biopharma stock or one of its competitors? Hillstream Biopharma's main competitors and comparable companies include Acacia Research (ACTG), Forward Industries (FWDI), Maase (MAAS), Cantor Equity Partners (CEPO), and TROOPS (TROO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "multi-sector holdings" industry.

How does Hillstream Biopharma compare to Acacia Research?

Acacia Research (NASDAQ:ACTG) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap finance companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

86.7% of Acacia Research shares are held by institutional investors. Comparatively, 1.2% of Hillstream Biopharma shares are held by institutional investors. 1.7% of Acacia Research shares are held by company insiders. Comparatively, 3.3% of Hillstream Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Acacia Research currently has a consensus target price of $6.00, indicating a potential upside of 29.87%. Given Acacia Research's stronger consensus rating and higher probable upside, analysts plainly believe Acacia Research is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acacia Research	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Acacia Research has higher revenue and earnings than Hillstream Biopharma. Acacia Research is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acacia Research	$285.23M	1.56	$21.68M	-$0.15	N/A
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A

Hillstream Biopharma has a net margin of 0.00% compared to Acacia Research's net margin of -5.39%. Acacia Research's return on equity of 0.44% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acacia Research	-5.39%	0.44%	0.33%
Hillstream Biopharma	N/A	-31.50%	-24.72%

Acacia Research has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market.

In the previous week, Acacia Research had 3 more articles in the media than Hillstream Biopharma. MarketBeat recorded 5 mentions for Acacia Research and 2 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 0.89 beat Acacia Research's score of 0.59 indicating that Hillstream Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acacia Research	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Hillstream Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Acacia Research beats Hillstream Biopharma on 10 of the 15 factors compared between the two stocks.

How does Hillstream Biopharma compare to Forward Industries?

Forward Industries (NASDAQ:FWDI) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap finance companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Forward Industries has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market.

Forward Industries presently has a consensus price target of $7.45, suggesting a potential upside of 74.07%. Given Forward Industries' stronger consensus rating and higher possible upside, equities analysts clearly believe Forward Industries is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forward Industries	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Forward Industries had 3 more articles in the media than Hillstream Biopharma. MarketBeat recorded 5 mentions for Forward Industries and 2 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 0.89 beat Forward Industries' score of -0.21 indicating that Hillstream Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forward Industries	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hillstream Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hillstream Biopharma has lower revenue, but higher earnings than Forward Industries. Forward Industries is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forward Industries	$18.19M	17.57	-$166.97M	-$2.05	N/A
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A

Hillstream Biopharma has a net margin of 0.00% compared to Forward Industries' net margin of -2,305.12%. Forward Industries' return on equity of -21.42% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forward Industries	-2,305.12%	-21.42%	-20.82%
Hillstream Biopharma	N/A	-31.50%	-24.72%

1.2% of Hillstream Biopharma shares are owned by institutional investors. 15.9% of Forward Industries shares are owned by insiders. Comparatively, 3.3% of Hillstream Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Forward Industries beats Hillstream Biopharma on 9 of the 16 factors compared between the two stocks.

How does Hillstream Biopharma compare to Maase?

Maase (NASDAQ:MAAS) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap finance companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maase	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Maase has a beta of 0.02, meaning that its share price is 98% less volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market.

1.2% of Hillstream Biopharma shares are held by institutional investors. 87.6% of Maase shares are held by insiders. Comparatively, 3.3% of Hillstream Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Maase has higher revenue and earnings than Hillstream Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maase	$784.35M	0.42	-$27.36M	N/A	N/A
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A

Maase's return on equity of 0.00% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maase	N/A	N/A	N/A
Hillstream Biopharma	N/A	-31.50%	-24.72%

In the previous week, Maase and Maase both had 2 articles in the media. Hillstream Biopharma's average media sentiment score of 0.89 beat Maase's score of 0.67 indicating that Hillstream Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maase	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hillstream Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Maase beats Hillstream Biopharma on 5 of the 8 factors compared between the two stocks.

How does Hillstream Biopharma compare to Cantor Equity Partners?

Cantor Equity Partners (NASDAQ:CEPO) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap finance companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

1.2% of Hillstream Biopharma shares are held by institutional investors. 3.3% of Hillstream Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Cantor Equity Partners had 1 more articles in the media than Hillstream Biopharma. MarketBeat recorded 3 mentions for Cantor Equity Partners and 2 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 0.89 beat Cantor Equity Partners' score of 0.53 indicating that Hillstream Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cantor Equity Partners	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hillstream Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cantor Equity Partners' return on equity of 0.00% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cantor Equity Partners	N/A	N/A	-2.95%
Hillstream Biopharma	N/A	-31.50%	-24.72%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cantor Equity Partners	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cantor Equity Partners has a beta of -0.05, indicating that its share price is 105% less volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market.

Cantor Equity Partners is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cantor Equity Partners	N/A	N/A	-$6.66M	-$0.47	N/A
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A

Summary

Cantor Equity Partners and Hillstream Biopharma tied by winning 5 of the 10 factors compared between the two stocks.

How does Hillstream Biopharma compare to TROOPS?

Hillstream Biopharma (NASDAQ:CNTN) and TROOPS (NASDAQ:TROO) are both small-cap finance companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

In the previous week, TROOPS had 2 more articles in the media than Hillstream Biopharma. MarketBeat recorded 4 mentions for TROOPS and 2 mentions for Hillstream Biopharma. Hillstream Biopharma's average media sentiment score of 0.89 beat TROOPS's score of -0.31 indicating that Hillstream Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hillstream Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TROOPS	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

TROOPS has higher revenue and earnings than Hillstream Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A
TROOPS	$17.10M	14.00	-$27.91M	N/A	N/A

TROOPS's return on equity of 0.00% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-31.50%	-24.72%
TROOPS	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TROOPS	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Hillstream Biopharma has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market. Comparatively, TROOPS has a beta of 3.49, meaning that its stock price is 249% more volatile than the broader market.

1.2% of Hillstream Biopharma shares are owned by institutional investors. 3.3% of Hillstream Biopharma shares are owned by company insiders. Comparatively, 1.1% of TROOPS shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

TROOPS beats Hillstream Biopharma on 6 of the 9 factors compared between the two stocks.

Get Hillstream Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNTN vs. The Competition

Export

Metric	Hillstream Biopharma	Financial Services Industry	Finance Sector	NASDAQ Exchange
Market Cap	$146.53M	$27.04B	$14.00B	$12.83B
Dividend Yield	N/A	5.98%	5.89%	10.06%
P/E Ratio	-1.65	16.55	29.14	24.76
Price / Sales	N/A	400.19	503.69	95.42
Price / Cash	N/A	45.57	30.22	37.42
Price / Book	0.17	3.17	3.72	6.45
Net Income	-$35.92M	$1.08B	$1.31B	$347.05M
7 Day Performance	-0.52%	-1.02%	0.00%	0.99%
1 Month Performance	-20.17%	-1.12%	0.95%	-0.64%
1 Year Performance	N/A	-9.39%	13.24%	22.27%

Hillstream Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNTN Hillstream Biopharma	0.3529 of 5 stars	$1.90 +1.6%	N/A	N/A	$146.53M	N/A	N/A	2
ACTG Acacia Research	2.7286 of 5 stars	$4.61 -0.4%	$6.00 +30.2%	+46.8%	$447.21M	$285.23M	N/A	1,036	Earnings Report
FWDI Forward Industries	2.6887 of 5 stars	$4.22 +3.7%	$7.45 +76.5%	N/A	$303.95M	$18.19M	N/A	100	Analyst Downgrade
MAAS Maase	0.7207 of 5 stars	$19.51 +5.5%	N/A	+493.1%	$294.31M	$109.05M	N/A	550	Gap Up
CEPO Cantor Equity Partners	0.769 of 5 stars	$10.65 -0.1%	N/A	+0.9%	$271.83M	N/A	N/A	2

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNTN) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hillstream Biopharma (CNTN) Competitors

CNTN vs. ACTG, FWDI, MAAS, CEPO, and TROO

How does Hillstream Biopharma compare to Acacia Research?

Summary

How does Hillstream Biopharma compare to Forward Industries?

Summary

How does Hillstream Biopharma compare to Maase?

Summary

How does Hillstream Biopharma compare to Cantor Equity Partners?

Summary

How does Hillstream Biopharma compare to TROOPS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTN vs. The Competition

Hillstream Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hillstream Biopharma (CNTN) Competitors

CNTN vs. ACTG, FWDI, MAAS, CEPO, and TROO

How does Hillstream Biopharma compare to Acacia Research?

Do institutionals & insiders believe in ACTG or CNTN?

Do analysts recommend ACTG or CNTN?

Which has stronger valuation & earnings, ACTG or CNTN?

Is ACTG or CNTN more profitable?

Which has more volatility and risk, ACTG or CNTN?

Does the media favor ACTG or CNTN?

Summary

How does Hillstream Biopharma compare to Forward Industries?

Which has more risk & volatility, FWDI or CNTN?

Do analysts rate FWDI or CNTN?

Does the media favor FWDI or CNTN?

Which has higher earnings & valuation, FWDI or CNTN?

Is FWDI or CNTN more profitable?

Do insiders & institutionals hold more shares of FWDI or CNTN?

Summary

How does Hillstream Biopharma compare to Maase?

Do analysts rate MAAS or CNTN?

Which has more risk and volatility, MAAS or CNTN?

Do insiders & institutionals believe in MAAS or CNTN?

Which has preferable earnings and valuation, MAAS or CNTN?

Is MAAS or CNTN more profitable?

Does the media favor MAAS or CNTN?

Summary

How does Hillstream Biopharma compare to Cantor Equity Partners?

Do insiders and institutionals hold more shares of CEPO or CNTN?

Does the media prefer CEPO or CNTN?

Is CEPO or CNTN more profitable?

Do analysts recommend CEPO or CNTN?

Which has more volatility & risk, CEPO or CNTN?

Which has better valuation & earnings, CEPO or CNTN?

Summary

How does Hillstream Biopharma compare to TROOPS?

Does the media refer more to CNTN or TROO?

Which has higher earnings and valuation, CNTN or TROO?

Is CNTN or TROO more profitable?

Do analysts recommend CNTN or TROO?

Which has more volatility & risk, CNTN or TROO?

Do insiders and institutionals believe in CNTN or TROO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTN vs. The Competition

Hillstream Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools